
Daniel D Buchanan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8246655/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genetics, 2006, 38, 787-793.	21.4	1,715
2	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	7.4	443
3	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	21.4	377
4	Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology, 2015, 148, 77-87.e2.	1.3	342
5	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 404-412.	2.5	341
6	Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. Journal of the National Cancer Institute, 2010, 102, 193-201.	6.3	328
7	Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. Cancer Research, 2014, 74, 3238-3247.	0.9	317
8	Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study. Journal of Clinical Oncology, 2012, 30, 958-964.	1.6	286
9	Correlation of tumour BRAF mutations and <i>MLH1</i> methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. Journal of Medical Genetics, 2012, 49, 151-157.	3.2	253
10	Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a †fusion' pathway to colorectal cancer. Histopathology, 2006, 49, 121-131.	2.9	230
11	Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology, 2018, 154, 2152-2164.e19.	1.3	226
12	Cancer Risks for <i>MLH1</i> and <i>MSH2</i> Mutation Carriers. Human Mutation, 2013, 34, 490-497.	2.5	201
13	Tumor Mismatch Repair Immunohistochemistry and DNA <i>MLH1</i> Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. Journal of Clinical Oncology, 2014, 32, 90-100.	1.6	195
14	Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome. Journal of the National Cancer Institute, 2012, 104, 1363-1372.	6.3	193
15	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	12.8	193
16	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 2005, 58, 829-839.	5.3	191
17	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. British Journal of Cancer, 2013, 108, 1757-1764.	6.4	191
18	Hyperplastic Polyposis Syndrome: Phenotypic Presentations and the Role of MBD4 and MYH. Gastroenterology, 2006, 131, 30-39.	1.3	186

#	Article	IF	CITATIONS
19	Risk of Colorectal Cancer for Carriers of Mutations in MUTYH, WithÂand Without a Family History of Cancer. Gastroenterology, 2014, 146, 1208-1211.e5.	1.3	180
20	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
21	Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Annals of Oncology, 2017, 28, 1023-1031.	1.2	174
22	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 2019, 10, 2154.	12.8	172
23	Tau haplotypes regulate transcription and are associated with Parkinson's disease. Annals of Neurology, 2004, 55, 329-334.	5.3	157
24	DNA methylationâ€based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies. International Journal of Cancer, 2018, 142, 1611-1619.	5.1	153
25	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
26	Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 2006, 55, 1467-1474.	12.1	131
27	Quality Assessment and Correlation of Microsatellite Instability and Immunohistochemical Markers among Population- and Clinic-Based Colorectal Tumors. Journal of Molecular Diagnostics, 2011, 13, 271-281.	2.8	131
28	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	6.3	129
29	Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Human Molecular Genetics, 2014, 23, 4729-4737.	2.9	128
30	Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Modern Pathology, 2013, 26, 1642-1656.	5.5	127
31	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology, 2013, 26, 825-834.	5.5	126
32	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 2013, 37, 1592-1602.	3.7	125
33	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. American Journal of Human Genetics, 2020, 107, 432-444.	6.2	124
34	Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clinical Gastroenterology and Hepatology, 2005, 3, 254-263.	4.4	123
35	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell, 2019, 35, 256-266.e5.	16.8	123
36	PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival. PLoS ONE, 2013, 8, e65479.	2.5	117

#	Article	IF	CITATIONS
37	<i>BRAF</i> Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1792-1798.	2.5	113
38	The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology, 2018, 29, 2240-2246.	1.2	113
39	Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology, 2020, 158, 1274-1286.e12.	1.3	110
40	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer. JAMA Surgery, 2021, 156, 865.	4.3	110
41	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Scientific Reports, 2015, 5, 10442.	3.3	109
42	Risk of extracolonic cancers for people with biallelic and monoallelic mutations in <i>MUTYH</i> . International Journal of Cancer, 2016, 139, 1557-1563.	5.1	107
43	Association of DNA Methylation-Based Biological Age With Health Risk Factors and Overall and Cause-Specific Mortality. American Journal of Epidemiology, 2018, 187, 529-538.	3.4	106
44	Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers. Annals of Surgical Oncology, 2013, 20, 1829-1836.	1.5	103
45	Telomere Length Varies By DNA Extraction Method: Implications for Epidemiologic Research. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2047-2054.	2.5	100
46	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.9	100
47	Ethnicity and Risk for Colorectal Cancers Showing Somatic <i>BRAF</i> V600E Mutation or CpG Island Methylator Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1774-1780.	2.5	96
48	Cancer risks for monoallelic <i>MUTYH</i> mutation carriers with a family history of colorectal cancer. International Journal of Cancer, 2011, 129, 2256-2262.	5.1	93
49	Risks of Colorectal and Other Cancers After Endometrial Cancer for Women With Lynch Syndrome. Journal of the National Cancer Institute, 2013, 105, 274-279.	6.3	93
50	Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients. Clinical Cancer Research, 2008, 14, 1692-1700.	7.0	91
51	Lynch Syndrome–Associated Breast Cancers: Clinicopathologic Characteristics of a Case Series from the Colon Cancer Family Registry. Clinical Cancer Research, 2010, 16, 2214-2224.	7.0	91
52	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology, 2020, 158, 1300-1312.e20.	1.3	90
53	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
54	GermlineTP53Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncology, 2015, 1, 214.	7.1	87

#	Article	IF	CITATIONS
55	Phenotype and Polyp Landscape in Serrated Polyposis Syndrome. American Journal of Surgical Pathology, 2012, 36, 876-882.	3.7	85
56	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. International Journal of Cancer, 2018, 142, 238-250.	5.1	83
57	Movement Disorders, 1999, 14, 219-224.	3.9	82
58	A Multifactorial Likelihood Model for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry. Human Mutation, 2013, 34, 200-209.	2.5	81
59	Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. European Journal of Cancer, 2017, 84, 228-238.	2.8	81
60	Cancer Risks for Relatives of Patients With Serrated Polyposis. American Journal of Gastroenterology, 2012, 107, 770-778.	0.4	80
61	Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. Journal of the National Cancer Institute, 2015, 107, djv170.	6.3	80
62	Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International Journal of Cancer, 2017, 140, 2701-2708.	5.1	76
63	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Medicine, 2020, 18, 396.	5.5	76
64	Promoter methylation of Wnt antagonists <i>DKK1</i> and <i>SFRP1</i> is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis, 2011, 32, 741-747.	2.8	74
65	Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin. Neurobiology of Disease, 2014, 62, 172-178.	4.4	74
66	Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Modern Pathology, 2012, 25, 722-730.	5.5	73
67	Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 512-519.	2.5	71
68	Tumour <i>MLH1</i> promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). Journal of Medical Genetics, 2014, 51, 789-796.	3.2	69
69	Risk Factors for Colorectal Cancer in Patients with Multiple Serrated Polyps: A Cross-Sectional Case Series from Genetics Clinics. PLoS ONE, 2010, 5, e11636.	2.5	68
70	Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). The Application of Clinical Genetics, 2014, 7, 183.	3.0	68
71	Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2015, 314, 61.	7.4	68
72	Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. International Journal of Epidemiology, 2012, 41, 1060-1072.	1.9	65

#	Article	IF	CITATIONS
73	Classifying <i>MLH1</i> and <i>MSH2</i> variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Human Mutation, 2009, 30, 757-770.	2.5	60
74	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. Breast Cancer Research, 2007, 9, R82.	5.0	58
75	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
76	The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neuroscience Letters, 2002, 327, 91-94.	2.1	57
77	Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. British Journal of Cancer, 2016, 115, 266-272.	6.4	57
78	Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing. Clinical Colorectal Cancer, 2018, 17, e293-e305.	2.3	55
79	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nature Communications, 2020, 11, 3644.	12.8	55
80	The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner. Journal of Biological Chemistry, 2014, 289, 25306-25316.	3.4	53
81	Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism and Related Disorders, 2009, 15, 105-109.	2.2	52
82	Novel associations between blood DNA methylation and body mass index in middle-aged and older adults. International Journal of Obesity, 2018, 42, 887-896.	3.4	52
83	KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Human Pathology, 2012, 43, 1177-1183.	2.0	51
84	Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. British Journal of Cancer, 2011, 105, 162-169.	6.4	50
85	Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genetics in Medicine, 2018, 20, 890-895.	2.4	49
86	Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. International Journal of Colorectal Disease, 2010, 25, 703-712.	2.2	48
87	A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. Journal of Medical Genetics, 2008, 45, 340-345.	3.2	47
88	Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 427-438.	2.8	47
89	Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. Clinical Epigenetics, 2020, 12, 5.	4.1	47
90	Potential impact of family history–based screening guidelines on the detection of earlyâ€onset colorectal cancer. Cancer, 2020, 126, 3013-3020.	4.1	45

#	Article	IF	CITATIONS
91	High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Familial Cancer, 2014, 13, 573-582.	1.9	44
92	Should the grading of colorectal adenocarcinoma include microsatellite instability status?. Human Pathology, 2014, 45, 2077-2084.	2.0	44
93	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1229-1238.	2.5	44
94	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. Human Genetics, 2019, 138, 307-326.	3.8	44
95	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	12.1	44
96	Mutation deep within an intron of MSH2 causes Lynch syndrome. Familial Cancer, 2011, 10, 297-301.	1.9	43
97	Confirmation of Linkage to and Localization of Familial Colon Cancer Risk Haplotype on Chromosome 9q22. Cancer Research, 2010, 70, 5409-5418.	0.9	42
98	Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer screening. Future Oncology, 2016, 12, 503-513.	2.4	42
99	Lack of evidence for germline <i>RNF43</i> mutations in patients with serrated polyposis syndrome from a large multinational study. Gut, 2017, 66, 1170-1172.	12.1	42
100	Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer. Epigenetics, 2013, 8, 748-755.	2.7	41
101	Determining the frequency of de novo germline mutations in DNA mismatch repair genes. Journal of Medical Genetics, 2011, 48, 530-534.	3.2	40
102	Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. Gut, 2015, 64, 101-110.	12.1	40
103	Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC). International Journal of Epidemiology, 2018, 47, 387-388i.	1.9	40
104	Biological Aging Measures Based on Blood DNA Methylation and Risk of Cancer: A Prospective Study. JNCI Cancer Spectrum, 2021, 5, pkaa109.	2.9	40
105	Multiplicity and Molecular Heterogeneity of Colorectal Carcinomas in Individuals With Serrated Polyposis. American Journal of Surgical Pathology, 2013, 37, 434-442.	3.7	39
106	Characterisation of Familial Colorectal Cancer Type X, Lynch syndrome, and non-familial colorectal cancer. British Journal of Cancer, 2014, 111, 598-602.	6.4	38
107	Identification of Novel Variants in Colorectal Cancer Families by High-Throughput Exome Sequencing. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1239-1251.	2.5	37
108	Variation at 2q35 (<i>PNKD</i> and <i>TMBIM1</i>) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease. Human Molecular Genetics, 2016, 25, 2349-2359.	2.9	37

#	Article	IF	CITATIONS
109	Alcohol Consumption and the Risk of Colorectal Cancer for Mismatch Repair Gene Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 366-375.	2.5	37
110	DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. , 2021, 9, e002671.		37
111	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	3.3	35
112	Dietary intake of one-carbon metabolism nutrients and DNA methylation in peripheral blood. American Journal of Clinical Nutrition, 2018, 108, 611-621.	4.7	35
113	Mendelian randomization analysis of C-reactive protein on colorectal cancer risk. International Journal of Epidemiology, 2019, 48, 767-780.	1.9	35
114	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
115	Genome-Wide Search for Gene-Gene Interactions in Colorectal Cancer. PLoS ONE, 2012, 7, e52535.	2.5	35
116	Endometrial cancer risk and survival by tumor MMR status. Journal of Gynecologic Oncology, 2018, 29, e39.	2.2	34
117	Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. Gastroenterology, 2020, 158, 2158-2168.e4.	1.3	34
118	Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. British Journal of Cancer, 2011, 104, 1906-1912.	6.4	33
119	Germline mutations in <i>PMS2</i> and <i>MLH1</i> in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort. BMJ Open, 2016, 6, e010293.	1.9	33
120	Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study. International Journal of Cancer, 2016, 139, 1081-1090.	5.1	32
121	Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Molecular Genetics & Genomic Medicine, 2017, 5, 553-569.	1.2	32
122	DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome. Modern Pathology, 2018, 31, 1608-1618.	5.5	32
123	Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?. European Journal of Cancer, 2013, 49, 1578-1587.	2.8	31
124	A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study. Carcinogenesis, 2014, 35, 2512-2519.	2.8	30
125	Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1130-1137.	2.5	30
126	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 2017, 147, 381-387.	1.4	30

#	Article	IF	CITATIONS
127	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
128	Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics, 2004, 5, 115-119.	1.4	28
129	Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome. PLoS ONE, 2013, 8, e66705.	2.5	27
130	Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. International Journal of Epidemiology, 2016, 45, 940-953.	1.9	27
131	Lifetime alcohol intake is associated with an increased risk of <i>KRAS</i> + and <i>BRAF</i> â€f <i>KRAS</i> ―but not <i>BRAF+</i> colorectal cancer. International Journal of Cancer, 2017, 140, 1485-1493.	5.1	27
132	Systematic meta-analyses, field synopsis and global assessment of the evidence of genetic association studies in colorectal cancer. Gut, 2020, 69, 1460-1471.	12.1	27
133	Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut, 2021, 70, 2138-2149.	12.1	27
134	Association of APOE with Parkinson disease age-at-onset in women. Neuroscience Letters, 2007, 411, 185-188.	2.1	26
135	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 2013, 132, 2876-2883.	5.1	26
136	Genomeâ€wide association study and metaâ€analysis in Northern European populations replicate multiple colorectal cancer risk loci. International Journal of Cancer, 2018, 142, 540-546.	5.1	26
137	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. Cancer Research, 2020, 80, 4578-4590.	0.9	26
138	Colorectal Cancer Linkage on Chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS ONE, 2012, 7, e38175.	2.5	24
139	Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer. Cancer Epidemiology, 2013, 37, 424-427.	1.9	24
140	Family History of Colorectal Cancer in <i>BRAF</i> p.V600E-Mutated Colorectal Cancer Cases. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 917-926.	2.5	24
141	Hyperplastic polyp of the duodenum: a report of 9 cases with immunohistochemical and molecular findings. Human Pathology, 2011, 42, 1953-1959.	2.0	23
142	The Association of Telomere Length with Colorectal Cancer Differs by the Age of Cancer Onset. Clinical and Translational Gastroenterology, 2014, 5, e52.	2.5	23
143	Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 2017, 8, 93450-93463.	1.8	23
144	Physical activity and the risk of colorectal cancer in Lynch syndrome. International Journal of Cancer, 2018, 143, 2250-2260.	5.1	23

#	Article	IF	CITATIONS
145	Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history. Familial Cancer, 2019, 18, 389-397.	1.9	23
146	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	6.2	23
147	The ACE Deletion Polymorphism Is Not Associated with Parkinson's Disease. European Neurology, 1999, 41, 103-106.	1.4	22
148	SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i> -Methylated Colorectal Cancer. Clinical Cancer Research, 2016, 22, 6266-6277.	7.0	22
149	Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 900-908.	2.5	22
150	The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. Parkinsonism and Related Disorders, 2001, 7, 89-91.	2.2	21
151	Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. Familial Cancer, 2009, 8, 313-323.	1.9	21
152	Do serrated neoplasms of the small intestine represent a distinct entity? Pathological findings and molecular alterations in a series of 13 cases. Histopathology, 2015, 66, 333-342.	2.9	21
153	Clinicopathologic Risk Factor Distributions for <i>MLH1</i> Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 68-75.	2.5	21
154	Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas. Familial Cancer, 2018, 17, 91-100.	1.9	21
155	Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family carrying an exon 7 nonsense variant in the AXIN2 gene. Familial Cancer, 2019, 18, 311-315.	1.9	20
156	Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. Gastroenterology, 2020, 159, 2241-2243.e6.	1.3	20
157	Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. Genetics in Medicine, 2020, 22, 1883-1886.	2.4	20
158	A Perspective on Bi-allelic MUTYH Mutations in Patients With Hyperplastic Polyposis Syndrome. Gastroenterology, 2009, 136, 2407-2408.	1.3	19
159	Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Familial Cancer, 2011, 10, 245-254.	1.9	19
160	Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with <i>Fusobacterium nucleatum</i> and Its Subspecies <i>animalis</i> . Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 210-220.	2.5	19
161	Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. ELife, 2022, 11, .	6.0	19
162	Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. Cancer Epidemiology, 2014, 38, 576-582.	1.9	18

#	Article	IF	CITATIONS
163	Stochastic Epigenetic Mutations Are Associated with Risk of Breast Cancer, Lung Cancer, and Mature B-cell Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2026-2037.	2.5	18
164	DNA Methylation Signatures and the Contribution of Age-Associated Methylomic Drift to Carcinogenesis in Early-Onset Colorectal Cancer. Cancers, 2021, 13, 2589.	3.7	18
165	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
166	Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: Correlation with KRAS mutation and the presence of endometriosis. Pathology, 2013, 45, 559-566.	0.6	17
167	Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. British Journal of Cancer, 2018, 118, 1639-1647.	6.4	16
168	RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers. Familial Cancer, 2018, 17, 63-69.	1.9	16
169	Assessment of a Polygenic Risk Score for Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer. JNCI Cancer Spectrum, 2021, 5, pkab022.	2.9	15
170	Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures. Nature Communications, 2022, 13, .	12.8	15
171	Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population. Journal of Neural Transmission, 2002, 109, 35-39.	2.8	14
172	Detection of large scale 3′ deletions in the PMS2 gene amongst Colon-CFR participants: have we been missing anything?. Familial Cancer, 2013, 12, 563-566.	1.9	14
173	Consequences of germline variation disrupting the constitutional translational initiation codon start sites of <i>MLH1</i> and <i>BRCA2</i> : Use of potential alternative start sites and implications for predicting variant pathogenicity. Molecular Carcinogenesis, 2015, 54, 513-522.	2.7	14
174	Lynch syndrome and cervical cancer. International Journal of Cancer, 2015, 137, 2757-2761.	5.1	13
175	Risk factors for metachronous colorectal cancer or polyp: A systematic review and metaâ€∎nalysis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 301-326.	2.8	13
176	Clinicoâ€pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service. Australasian Journal of Dermatology, 2019, 60, 126-133.	0.7	13
177	Cancer Risks for the Relatives of Colorectal Cancer Cases with a Methylated <i>MLH1</i> Promoter Region: Data from the Colorectal Cancer Family Registry. Cancer Prevention Research, 2012, 5, 328-335.	1.5	12
178	Risks of Colorectal Cancer and Cancer-Related Mortality in Familial Colorectal Cancer Type X and Lynch Syndrome Families. Journal of the National Cancer Institute, 2019, 111, 675-683.	6.3	12
179	A Genomic Test for Colorectal Cancer Risk: Is This Acceptable and Feasible in Primary Care?. Public Health Genomics, 2020, 23, 110-121.	1.0	12
180	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12

#	Article	IF	CITATIONS
181	Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome. Journal of Molecular Diagnostics, 2021, 23, 358-371.	2.8	12
182	Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry. PLoS ONE, 2016, 11, e0165436.	2.5	12
183	Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene. Familial Cancer, 2015, 14, 575-583.	1.9	11
184	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1737-1744.	2.8	11
185	DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports, 2018, 8, 1767.	3.3	11
186	Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 417-425.	1.1	11
187	Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. BioTechniques, 2019, 67, 118-122.	1.8	11
188	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	2.4	11
189	Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome. British Journal of Cancer, 2019, 121, 869-876.	6.4	10
190	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. Cancers, 2021, 13, 2088.	3.7	10
191	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	2.5	10
192	Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. Cancer, 2022, 128, 1157-1161.	4.1	10
193	Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynchâ€associated cancers—A populationâ€based analysis. Cancer Medicine, 2018, 7, 6411-6422.	2.8	9
194	Epigenetic Drift Association with Cancer Risk and Survival, and Modification by Sex. Cancers, 2021, 13, 1881.	3.7	9
195	Stability of BAT26 in Lynch syndrome colorectal tumours. European Journal of Human Genetics, 2007, 15, 139-141.	2.8	8
196	Cigarette pack labelling in 12 countries at different levels of economic development. Journal of Public Health Policy, 2011, 32, 146-164.	2.0	8
197	Absence of <i><scp>PMS2</scp></i> mutations in colonâ€ <scp>CFR</scp> participants whose colorectal cancers demonstrate unexplained loss of <scp>MLH1</scp> expression. Clinical Genetics, 2013, 83, 591-593.	2.0	8
198	Childhood cancers in families with and without Lynch syndrome. Familial Cancer, 2015, 14, 545-551.	1.9	8

#	Article	IF	CITATIONS
199	Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome. Molecular Genetics & Genomic Medicine, 2019, 7, e00781.	1.2	8
200	Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location. JNCI Cancer Spectrum, 2020, 4, pkaa042.	2.9	8
201	The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability. Clinical Epigenetics, 2020, 12, 102.	4.1	8
202	Association between Smoking and Molecular Subtypes of Colorectal Cancer. JNCI Cancer Spectrum, 2021, 5, pkab056.	2.9	8
203	Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers. Pathology, 2012, 44, 89-98.	0.6	7
204	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. BMC Cancer, 2016, 16, 113.	2.6	7
205	GWASeq: targeted re-sequencing follow up to GWAS. BMC Genomics, 2016, 17, 176.	2.8	7
206	Germline miRNA DNA variants and the risk of colorectal cancer by subtype. Genes Chromosomes and Cancer, 2017, 56, 177-184.	2.8	7
207	Functional informed genomeâ€wide interaction analysis of body mass index, diabetes and colorectal cancer risk. Cancer Medicine, 2020, 9, 3563-3573.	2.8	7
208	An integrated mass spectrometry imaging and digital pathology workflow for objective detection of colorectal tumours by unique atomic signatures. Chemical Science, 2021, 12, 10321-10333.	7.4	7
209	Informed choice and attitudes regarding a genomic test to predict risk of colorectal cancer in general practice. Patient Education and Counseling, 2022, 105, 987-995.	2.2	7
210	Impact of microsatellite status in early-onset colonic cancer. British Journal of Surgery, 2022, 109, 632-636.	0.3	7
211	Re: Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication. Journal of the National Cancer Institute, 2014, 106, dju180-dju180.	6.3	6
212	Cholecystectomy and the risk of colorectal cancer by tumor mismatch repair deficiency status. International Journal of Colorectal Disease, 2016, 31, 1451-1457.	2.2	6
213	Determining the familial risk distribution of colorectal cancer: a data mining approach. Familial Cancer, 2016, 15, 241-251.	1.9	6
214	Family history–based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios. PLoS Medicine, 2018, 15, e1002630.	8.4	6
215	Overall lack of replication of associations between dietary intake of folate and vitamin B-12 and DNA methylation in peripheral blood. American Journal of Clinical Nutrition, 2020, 111, 228-230.	4.7	6
216	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1349-1358.	2.5	6

#	Article	IF	CITATIONS
217	Genetic variants within the hTERT gene and the risk of colorectal cancer in Lynch syndrome. Genes and Cancer, 2015, 6, 445-451.	1.9	6
218	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. European Journal of Cancer, 2021, 159, 247-258.	2.8	6
219	Association of FOXO3 Blood DNA Methylation with Cancer Risk, Cancer Survival, and Mortality. Cells, 2021, 10, 3384.	4.1	6
220	Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival. Scientific Reports, 2022, 12, 127.	3.3	6
221	Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1077-1089.	2.5	6
222	Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer. Future Oncology, 2010, 6, 539-549.	2.4	5
223	Reply to J. Moline et al. Journal of Clinical Oncology, 2014, 32, 2278-2279.	1.6	5
224	Modeling of Successive Cancer Risks in Lynch Syndrome Families in the Presence of Competing Risks Using Copulas. Biometrics, 2017, 73, 271-282.	1.4	5
225	Response to Li and Hopper. American Journal of Human Genetics, 2021, 108, 527-529.	6.2	5
226	Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer. Familial Cancer, 2021, , 1.	1.9	5
227	Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. Cancer Prevention Research, 2022, 15, 447-454.	1.5	5
228	Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. New Zealand Medical Journal, 2017, 130, 57-67.	0.5	4
229	Rare Variants in the DNA Repair Pathway and the Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 895-903.	2.5	3
230	Tetranucleotide and Low Microsatellite Instability Are Inversely Associated with the CpG Island Methylator Phenotype in Colorectal Cancer. Cancers, 2021, 13, 3529.	3.7	3
231	Movement Disorders, 1999, 14, 219-224.	3.9	3
232	"Left in limboâ€: Exploring how patients with colorectal cancer interpret and respond to a suspected Lynch syndrome diagnosis. Hereditary Cancer in Clinical Practice, 2021, 19, 43.	1.5	3
233	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. Nutrients, 2021, 13, 4164.	4.1	3
234	Heterogeneity in the psychosocial and behavioral responses associated with a diagnosis of suspected Lynch syndrome in women with endometrial cancer. Hereditary Cancer in Clinical Practice, 2022, 20, .	1.5	3

#	Article	IF	CITATIONS
235	Utility of immunohistochemistry for mismatch repair proteins on colorectal polyps in the familial cancer clinic. Internal Medicine Journal, 2018, 48, 1325-1330.	0.8	2
236	Assessing the ProMCol classifier as a prognostic marker for non-metastatic colorectal cancer within the Melbourne Collaborative Cohort Study. Gut, 2019, 68, 761-762.	12.1	2
237	Genetic variants associated with circulating Câ€reactive protein levels and colorectal cancer survival: Sexâ€specific and lifestyle factors specific associations. International Journal of Cancer, 2022, 150, 1447-1454.	5.1	2
238	Diabetes mellitus in relation to colorectal tumor molecular subtypes ―a pooled analysis of more than 9,000 cases. International Journal of Cancer, 2022, , .	5.1	2
239	Cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency. Genetics in Medicine, 2022, 24, 1821-1830.	2.4	2
240	Does genetic predisposition modify the effect of lifestyle-related factors on DNA methylation?. Epigenetics, 2022, 17, 1838-1847.	2.7	2
241	Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins. Modern Pathology, 2013, 26, 944-954.	5.5	1
242	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-Tumor Phenotype Including a Predisposition to Colon and Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	1
243	Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2719-2728.	2.5	1
244	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1068-1076.	2.5	1
245	Association between germline variants and somatic mutations in colorectal cancer. Scientific Reports, 2022, 12, .	3.3	1
246	Molecular subtypes of colorectal cancer in relation to disease survival Journal of Clinical Oncology, 2014, 32, 451-451.	1.6	0
247	OUP accepted manuscript. Journal of the National Cancer Institute, 2022, , .	6.3	0